Related Experiment Video
Updated: Mar 31, 2026
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays
Insights
This study establishes reference ranges for the S100B biomarker in children and pregnant women, crucial for managing traumatic brain injury. Analytical performances were validated on two analyzers, aiding clinical interpretation.
Area of Science:
- Biomarker analysis
- Clinical chemistry
- Pediatric and obstetric medicine
Background:
- Traumatic brain injury (TBI) management in children and pregnant women is challenging due to imaging risks.
- S100B is a well-established biomarker requiring defined reference ranges for these populations.
- This study addresses the need for reliable S100B testing in pediatric and pregnancy contexts.
Purpose of the Study:
- To determine analytical performances and reference ranges for serum S100B.
- To evaluate S100B testing in children under 16 and pregnant women.
- To compare results between DiaSorin® Liaison XL and Roche Diagnostics® Cobas e411 analyzers.
Main Methods:
- Chemiluminescent immunoassay used for serum S100B determination.
- Analysis performed on 409 healthy children (0-16 years) and 50 pregnant women.
- Investigated analytical performances, and influence of blood cells and skin pigmentation.
Main Results:
- Established age-specific S100B reference ranges for children (0-3m, 4-9m, 10-24m, 2-16y).
- Serum S100B levels in pregnant women were comparable to adult ranges and consistent across trimesters.
- S100B expression found in lymphocytes; skin pigmentation influenced results; both analyzers showed good performance.
Conclusions:
- The data provides essential reference values for interpreting S100B results in pediatric and pregnancy settings.
- Understanding preanalytical conditions and analytical performance is key for accurate S100B testing.
- This research supports improved TBI management in vulnerable populations.
Background:
Traumatic brain injury management is a tricky issue in children and pregnant women (due to adverse effects of computer tomography). To facilitate management, we report the main analytical performances and reference ranges for blood tests for the well-established S100B biomarker in under-16 children on a DiaSorin® Liaison XL analyzer and in pregnant women on DiaSorin® Liaison XL and Roche Diagnostics® Cobas e411 analyzers.
Methods:
Serum S100B concentrations were determined by chemiluminescent immunoassay on a DiaSorin® analyzer in a population of 409 healthy children aged 0-16 years and on DiaSorin®/Roche Diagnostics® instruments in a population of 50 pregnant women (one blood sample for each trimester). The analytical performances of both instruments and the influence of blood cells and skin pigmentation on the assay were also studied.
Results:
For children, four age-groups emerged, i.e. 0-3 months (mean: 0.97 μg/L; standard deviation (SD): 0.36; 95th percentile: 1.55), 4-9 months (mean: 0.58 μg/L; SD: 0.30; 95th: 1.18), 10-24 months (mean: 0.31 μg/L; SD: 0.12; 95th: 0.54) and 2-16 years (mean: 0.20 μg/L; SD: 0.07; 95th: 0.32). For pregnant women, serum S100B concentrations were similar to defined ranges for adults and not significantly different between trimesters on DiaSorin® (p=0.652)/Roche Diagnostics® (p=0.877) analyzers. We also found S100B expression (protein, total mRNA) in lymphocytes, an influence of skin pigmentation, and good analytical performances for both instruments.
Conclusions:
Data provided here is useful for interpreting serum S100B test results, in terms of preanalytical conditions, analytical performances, pediatric and pregnancy' environment.
